Table 1 Association of LVD and LVI with other clinicopathological parameters

Age (y)*

≧55

42

22.1 ± 8.9

10.1 ± 5.1

17/25

1567 ± 138

1658

<55

40

20.8 ± 7.9

11.2 ± 5.1

21/19

1856 ± 241

1864

Gender

male

63

21.0 ± 7.9

11.2 ± 4.9

27/36

1795 ± 183

1658

female

19

23.2 ± 9.9

8.7 ± 5.5

11/8

1578 ± 214

1577

Histologic type

Squamous cell

31

19.7 ± 6.4

9.6 ± 4.6

14/17

1664 ± 189

1972

Adenocarcinoma

41

22.4 ± 9.5

11.0 ± 5.1

20/21

1815 ± 231

1337

Large cell

10

23.4 ± 9.1

12.4 ± 6.1

4/6

1134 ± 156

1118

Tumor differentiation

Well-moderate

44

21.3 ± 8.6

10.5 ± 5.4

20/24

2085 ± 220

1900

Poor

38

21.7 ± 8.3

10.8 ± 5.0

18/20

1325 ± 154

1118

Pathologic N stage

N1–2

44

24.2 ± 8.9^#

10.6 ± 5.4

15/29^#

943 ± 107^#

674

N0

38

18.4 ± 6.7

11.7 ± 4.7

22/16

2725 ± 213

2545

Pathologic T stage

T2–3

51

20.9 ± 8.6

11.4 ± 5.2

21/30

1449 ± 149

1223

T1

31

22.5 ± 8.0

9.5 ± 4.8

17/14

1875 ± 172

1775

BVI

BVI+

39

23.2 ± 9.8

9.8 ± 4.3

21/18

1321 ± 146

1117

BVI-

43

19.9 ± 6.6

11.3 ± 5.7

12/21

2083 ± 230

2031

ptLVD*

High(≥19.9)

41

/

12.7 ± 5.6

13/28^#

1171 ± 153^#

772

Low(<19.9)

41

/

12.2 ± 4.9

25/16

2378 ± 224

2057

itLVD*

High(≥10.2)

46

22.9 ± 7.4

/

23/23

1749 ± 229

1577

Low(<10.2)

36

23.3 ± 6.7

/

15/21

1675 ± 162

1658

LVI

LVI+

46

24.0 ± 9.3^#

10.9 ± 5.4

/

1212 ± 125^#

1006

LVI-

36

18.2 ± 5.8

10.3 ± 4.7

/

2433 ± 245

2123

Pathologic stage

I+II

48

19.4 ± 7.6^#

10.8 ± 4.9

26/22^#

2501 ± 202^#

2115

III+IV

34

24.5 ± 8.7

10.4 ± 5.4

11/23

800 ± 105

621

VEGF-C

Positive

61

23.1 ± 8.5^#

10.6 ± 5.0

24/37^#

1519 ± 173^#

1117

Negative

21

16.9 ± 6.0

10.7 ± 5.7

14/7

2232 ± 194

1981

Ki67/%*

High(≥3.56)

50

24.2 ± 9.2^#

12.9 ± 4.4

21/29^#

1322 ± 135^#

1109

Low(<3.56)

32

17.2 ± 4.8

13.3 ± 5.0

21/11

2431 ± 235

2024